2007 The Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics
Dr. Diamandis is division head of clinical biochemistry in the department of pathology and laboratory medicine at Mount Sinai Hospital; biochemist-in-chief at the University Health Network and Toronto Medical Laboratories; and division head of clinical biochemistry in the department of laboratory medicine and pathobiology at the University of Toronto in Ontario, Canada. Dr. Diamandis has been active in the field of cancer diagnostics over the past 20 years. He currently chairs the National Academy of Clinical Biochemistry effort to develop guidelines for the clinical use of tumor markers. His main research interests are tumor markers, especially a group of enzymes called human tissue kallikreins. His most recent research focuses on proteomic methodologies for identifying novel cancer biomarkers and the physiology of kallikrein enzymes, as they relate to cancer initiation and progression. He is also conducting research to validate multiparametric panels for early ovarian, breast, and prostate cancer diagnosis. Dr. Diamandis serves on the boards of 25 journals. He has published more than 400 original papers and holds 13 patents, with another 20 pending. He co-authored a recent textbook, Tumor Markers. For many years, he has run workshops on tumor markers and proteomic technologies at the AACC annual meetings.